AU2021339892A1 - Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof - Google Patents
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof Download PDFInfo
- Publication number
- AU2021339892A1 AU2021339892A1 AU2021339892A AU2021339892A AU2021339892A1 AU 2021339892 A1 AU2021339892 A1 AU 2021339892A1 AU 2021339892 A AU2021339892 A AU 2021339892A AU 2021339892 A AU2021339892 A AU 2021339892A AU 2021339892 A1 AU2021339892 A1 AU 2021339892A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- antibody
- linker
- gly
- glp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077983P | 2020-09-14 | 2020-09-14 | |
| US63/077,983 | 2020-09-14 | ||
| PCT/US2021/050337 WO2022056494A1 (en) | 2020-09-14 | 2021-09-14 | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021339892A1 true AU2021339892A1 (en) | 2023-04-27 |
| AU2021339892A9 AU2021339892A9 (en) | 2024-02-08 |
Family
ID=78080567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021339892A Pending AU2021339892A1 (en) | 2020-09-14 | 2021-09-14 | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12280124B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210767A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023542295A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230070337A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116615251A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021339892A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191304A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2023000678A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023004558A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301074A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002974A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022056494A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023542295A (ja) | 2020-09-14 | 2023-10-06 | リジェネロン ファーマシューティカルズ,インク. | Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用 |
| CA3243669A1 (en) | 2022-03-11 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES |
| CN119731206A (zh) * | 2022-08-01 | 2025-03-28 | 先为达生物美国有限公司 | 抗glp-1r抗体及其用途 |
| IL322391A (en) | 2023-02-27 | 2025-09-01 | Regeneron Pharma | Liquid-phase peptide-supported synthesis of peptides and peptide-like molecules |
| CN122295135A (zh) | 2023-11-03 | 2026-06-26 | 瑞泽恩制药公司 | 作为glp1r激动剂的肽酸及其抗体-药物缀合物 |
| IL330385A (en) * | 2023-12-29 | 2026-08-01 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Antibody-polypeptide conjugate and its pharmaceutical use |
| WO2026024847A2 (en) * | 2024-07-23 | 2026-01-29 | Baylor University | Chemical probes for microbial mucin degraders in the gut microbiome |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| US20060275288A1 (en) * | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| KR101277560B1 (ko) * | 2007-12-11 | 2013-06-25 | 카딜라 핼쓰캐어 리미티드 | 글루카곤 안타고니스트 활성 및 glp-1 아고니스트 활성의 펩티드 유사체 |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| ES2560807T3 (es) | 2008-07-21 | 2016-02-22 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| FR2937972B1 (fr) | 2008-11-04 | 2013-03-29 | Galderma Res & Dev | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| DK2889624T3 (en) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversible covalent bonding of functional molecules |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| WO2011048614A2 (en) * | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| EP2601298B1 (en) | 2010-08-02 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| US9911931B2 (en) | 2014-06-26 | 2018-03-06 | Universal Display Corporation | Organic electroluminescent materials and devices |
| GB2551945B (en) * | 2015-12-18 | 2021-09-08 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
| MX390630B (es) | 2016-01-25 | 2025-03-21 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. |
| EP3419670A2 (en) * | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| EP4480537A3 (en) * | 2017-01-17 | 2025-03-12 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| KR20250008984A (ko) * | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| MX2022014090A (es) | 2020-05-12 | 2023-02-27 | Regeneron Pharma | Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos. |
| JP2023542295A (ja) | 2020-09-14 | 2023-10-06 | リジェネロン ファーマシューティカルズ,インク. | Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用 |
-
2021
- 2021-09-14 JP JP2023516467A patent/JP2023542295A/ja active Pending
- 2021-09-14 EP EP21787235.7A patent/EP4210767A1/en active Pending
- 2021-09-14 AU AU2021339892A patent/AU2021339892A1/en active Pending
- 2021-09-14 CA CA3191304A patent/CA3191304A1/en active Pending
- 2021-09-14 MX MX2023002974A patent/MX2023002974A/es unknown
- 2021-09-14 KR KR1020237012710A patent/KR20230070337A/ko active Pending
- 2021-09-14 CN CN202180076678.6A patent/CN116615251A/zh active Pending
- 2021-09-14 WO PCT/US2021/050337 patent/WO2022056494A1/en not_active Ceased
- 2021-09-14 US US17/475,248 patent/US12280124B2/en active Active
- 2021-09-14 IL IL301074A patent/IL301074A/en unknown
-
2023
- 2023-03-09 CL CL2023000678A patent/CL2023000678A1/es unknown
- 2023-04-12 CO CONC2023/0004558A patent/CO2023004558A2/es unknown
-
2025
- 2025-01-16 US US19/023,874 patent/US20250161476A1/en active Pending
- 2025-08-21 CL CL2025002511A patent/CL2025002511A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022056494A1 (en) | 2022-03-17 |
| US12280124B2 (en) | 2025-04-22 |
| US20220096648A1 (en) | 2022-03-31 |
| AU2021339892A9 (en) | 2024-02-08 |
| MX2023002974A (es) | 2023-05-25 |
| CL2023000678A1 (es) | 2023-10-20 |
| CA3191304A1 (en) | 2022-03-17 |
| EP4210767A1 (en) | 2023-07-19 |
| CO2023004558A2 (es) | 2023-04-27 |
| KR20230070337A (ko) | 2023-05-22 |
| US20250161476A1 (en) | 2025-05-22 |
| CL2025002511A1 (es) | 2025-10-03 |
| JP2023542295A (ja) | 2023-10-06 |
| IL301074A (en) | 2023-05-01 |
| CN116615251A (zh) | 2023-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12280124B2 (en) | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | |
| JP7724196B2 (ja) | 免疫グロブリン及びその使用 | |
| US20230330254A1 (en) | Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof | |
| EP3901162A1 (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
| JP2024531480A (ja) | ステロイド化合物及びそのコンジュゲート | |
| JP2013503626A (ja) | グルカゴン受容体に対する抗体と、それらの使用 | |
| US20250171516A1 (en) | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof | |
| WO2025085489A1 (en) | Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof | |
| EA051876B1 (ru) | Конъюгаты антитело-лекарственное средство, содержащие пептидомиметики glp1, и их применения | |
| US20250270274A1 (en) | Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity | |
| IL325400A (en) | Anti-human CACNG1 antibody-drug conjugates and their uses | |
| WO2024182268A1 (en) | Liquid phase peptide support synthesis of peptides and peptidomimetics | |
| EA050796B1 (ru) | Иммуноглобулины и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |